MONT-SAINT-GUIBERT, Belgium, July 14, 2010
- Dr. Atta Behfar Recognised With Prestigious Award for Science BehindCardio3 BioSciences' C-Cure Technology
Cardio3 BioSciences, a leading Belgian biotechnology company specialisingin regenerative therapies for the treatment of cardiovascular diseases, todayannounces that Dr. Atta Behfar is joining its research and developmentlaboratories as Director for Advanced Research. Dr. Atta Behfar, one of thekey scientists involved in the development of C-Cure(R), will spend a year atCardio3 BioSciences on assignment from Mayo Clinic to develop and strengthenthe research pipeline.
Dr. Behfar is a member of the clinician investigator program incardiology at the Mayo Clinic in Rochester, Minnesota, USA and has played akey role in the research underlying Cardio3 BioSciences' lead product,C-Cure, a revolutionary stem cell treatment for heart failure. His work wasrecognised by the Herman K. Gold Young Investigator Award at the AnnualAmerican College of Cardiology meeting in March 2010, in Georgia, Atlantahighlighting the quality of the science behind Cardio3 BioSciences' approach.
C-Cure is designed to reprogram the patient's own stem cells into newheart cells to rebuild the heart. Dr Behfar has played an active part indeveloping the technology that directs the patient's cells to becomecardiopoietic cells - cells 'programmed' to become new heart muscle cellswhen injected back into the heart of a patient, replacing those cells lostduring heart failure and restoring heart function.
Cardio3 BioSciences has recently announced positive three-month safetydata and preliminary efficacy results from its Phase II stage clinical trialof C-Cure in heart failure. C-Cure demonstrated a very good safety profileand positive trends in physiological and clinical measures that suggest thatC-Cure, as anticipated from animal model data, is acting on heart muscle in away that could yield important clinical benefits
Dr. Behfar will work with Cardio3 BioSciences' scientific in-house teamas of July 1st, 2010, where he will have the opportunity to work directlywith the Company as it continues to further develop its unique technology.
Dr. Atta Behfar said: "It is a very exciting time for Cardio3 BioScienceswith C-Cure having shown encouraging early results in a clinical setting. Ilook forward to working with the in-house team as they further advance theproduct from being a scientific concept towards becoming a therapy that couldpotentially treat one of the world's greatest unmet medical needs. Manyadditional treatments may also be leveraged out of the science that lead toC-Cure discovery, and my role will be to fully develop the potential ofCardio3 BioSciences' unique technology."
Dr. Christian Homsy, CEO of Cardio3 BioSciences, added: "We are delightedthat Dr Behfar has chosen to come to work with Cardio3 BioSciences andbelieve this demonstrates not only the quality of the work carried out atCardio3 BioSciences but also the standard of research in Belgium moregenerally."
About Cardio3 BioSciences
Cardio3 BioSciences is a leading Belgian biotechnology companyspecialising in regenerative therapies for the treatment of cardiovasculardisease. The Company's lead product, C-Cure(R), is a highly innovativeapproach to the treatment of heart failure, one of the world's most pressingunmet medical needs. Based on a strategy developed by Cardio3 BioSciences'founders and leveraging technology licensed from Mayo Clinic, C-Cure isdesigned to reprogram the patient's own stem cells into new heart cells torebuild the heart.
The Cardio3 BioSciences team has extensive experience in developing andcommercialising new pharmaceutical products and medical technologies and theCompany's strategy is to drive the clinical development of C-Cure and tomarket the product itself in major territories.
Cardio3 BioSciences was founded in July 2007 and is based inMont-Saint-Guibert in the Walloon region of Belgium.
About C-Cure and Heart Failure
Heart failure is a serious and common condition in which the heart cannotpump enough blood through the body, leaving the patient debilitated andunable to conduct a normal life. It can result from heart attacks or a numberof other causes. Patients suffering from the condition can experienceshortness of breath and extreme exhaustion. It affects 28 million patientsworldwide and this number is predicted to double by 2020. Therapies availablefor chronic heart failure aim at slowing down the disease progression, butwith the exception of heart transplant, existing drugs or devices do not curechronic heart failure.
C-Cure is produced by taking a patient's own stem cells and, through aproprietary process, differentiating them into cardiopoietic cells that canregenerate damaged heart muscle. The cardiopoietic cells are injected intothe heart of a patient with heart failure where they are designed to behaveidentically to those cells lost in heart failure without carrying the risk ofrejection, something that has not been achieved with previous cell therapiesfor this indication. C-Cure is the outcome of multiple years of researchconducted at Mayo Clinic (Rochester, Minnesota, USA) and at theCardiovascular Center in Aalst (Aalst, Belgium).
Mayo Clinic holds equity in Cardio3 BioSciences as a result ofintellectual property licensed to the company.For more information contact: Cardio3 BioSciences Dr Christian Homsy, CEO Tel: +32-10-39-41-00 Anne Portzenheim, Communication Manager Tel : +32-10-39-41-00 firstname.lastname@example.org http://www.c3bs.com Citigate Dewe Rogerson Tel : +44(0)207-638-9571 Chris Gardner/Nina Enegren email@example.com Hill & Knowlton Tel : +32-2-737-95-00 Katia Delvaille firstname.lastname@example.org
SOURCE Cardio3 BioSciences